Analysis of the cure rate and long-term efficacy evaluation of zolbetuximab

Zolbetuximab (Zolbetuximab) is a new targeted drug mainly used to treat CLDN18.2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma. As a monoclonal antibody targeting tight junction protein 18.2 (Claudin18.2), zotuximab has shown good efficacy and safety in multiple international clinical trials, and is especially important in improving the survival of advanced patients. This article will combine clinical research data and the latest medical trends to conduct an in-depth evaluation of the cure rate, long-term efficacy and application prospects of zotuximab.

1. Target specificity and mechanism of action are the basis for therapeutic efficacy

The target of zotuximab is CLDN18.2, which is a subtype of the tight junction protein family. Normally, it is mainly expressed in gastric mucosal epithelial cells. However, during the process of malignant transformation, this protein shows abnormally high expression on the surface of various gastric cancer cells and rarely appears in normal tissues, making it an ideal target for targeted therapy. Zotuximab specifically binds to CLDN18.2-positive tumor cells and initiates antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms, thereby selectively killing tumor cells and inhibiting their growth and metastasis.

This precise mechanism of action not only improves the targeting and effectiveness of treatment, but also significantly reduces damage to normal tissues, thereby improving patient tolerance and treatment compliance. Especially in combination chemotherapy regimens, zotuximab has shown significant advantages in enhancing efficacy and prolonging progression-free survival (PFS) and overall survival (OS).

2. Clinical trials show significant survival benefit

The long-term efficacy of zotuximab mainly comes from a number of key clinical trials, especially the global multi-center SPOTLIGHT study and GLOW study. These studies mainly focus on CLDN18.2positive advanced gastric cancer patients who have not received systemic treatment.

In the SPOTLIGHT study, the chemotherapy regimen of zotuximab combined with mFOLFOX6 was compared with the chemotherapy alone group. The results showed that the median progression-free survival of the combination group was 1 0.6 months, while the chemotherapy control group was only 8.7 months; the median overall survival was 18.2 months vs. 15.5 months. Furthermore, the objective response rate (ORR) also improved from 48.8% to 57.8% in the chemotherapy group. These data demonstrate that zotuximab not only improves short-term efficacy but also achieves positive results in terms of long-term survival.

In the GLOW study, zotuximab was used in combination with CAPOX chemotherapy regimen in the same CLDN18 .2The efficacy was once again verified in the positive population, and the progression-free survival was extended to 8.2 months, which was significantly better than the 6.8 months in the control group. The results of these multi-center, high-quality studies provide solid data support for the long-term application of zotuximab.

3. The cure rate is still limited by the stage of the disease and individual differences.

Although zotuximab has a significant effect in prolonging survival time and improving response rate, "Cure" is still a very challenging goal in the current medical definition, especially for advanced solid tumors such as gastric cancer. Based on current clinical data, zotuximab has not yet shown the ability to completely cure advanced gastric cancer.

In the treatment of advanced tumors, more emphasis is placed on"disease control" and "survival with tumors", that is, long-term treatment can transform tumors into a chronic disease state, prolong life and improve quality of life. Judging from the current data, zotuximab is mainly suitable for patients with positive CLDN18.2 expression, and its efficacy may also be affected by individual differences, immune status, combination treatment options and basic health conditions. Therefore, for patients who expect a radical cure, this drug is more of a means of prolonging survival and controlling the disease, rather than a curative drug.

4. Long-term application safety and drug resistance issues still need to be studied

When treating advanced cancer, long-term drug safety is critical. The safety of zotuximab has performed well in current clinical studies. Its main adverse reactions are nausea, vomiting, loss of appetite, diarrhea, etc. The incidence of serious adverse events is relatively low and it is well tolerated by patients. However, as with all targeted drugs, the risk of secondary resistance after long-term use remains.

Resistance mechanisms may include down-regulation of CLDN18.2 expression levels by tumor cells, mutations in the antibody recognition region, or evasion of immune clearance by activating other escape pathways. The current research on the resistance mechanism of zotuximab is still in its early stages, but in future clinical practice, identifying resistance signals, adjusting treatment strategies, and even developing combination new drug regimens will be the key directions to improve its long-term efficacy.

Zotuximab as the first targetCLDN18.2’s antibody drugs provide a new direction for the precise treatment of malignant tumors such as advanced gastric cancer. Although the goal of "cure" cannot yet be achieved, it has been clinically verified in terms of prolonging survival, improving remission rate, and improving quality of life. With the expansion of indications and advancement of follow-up research, zotuximab is expected to become an important part of the future targeted treatment of gastric cancer. For CLDN18.2 positive patients, timely detection and treatment with this drug may significantly improve the long-term prognosis and is one of the important choices in current treatment decisions.

Reference materials:https://www.astellas.com/en/news/29401